Novo Nordisk's (NVO) weight loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries who are both obese and have cardiovascular disease, could cost the system up to $145B ...

This article summarizes recent health news, covering a spectrum of global issues. Highlights include Brazil's avian flu trade ...

Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...

How the change could impact Novo Nordisk. The amount Medicare spent on Ozempic, Wegovy, and Rybelsus between November 2023 and October 2024 represents roughly 36% of Wall Street's consensus ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Medicare is negotiating the prices of 15 drugs, including Novo Nordisk's Ozempic.The government has until Nov. 30 to announce the agreed-upon Medicare prices. The lower prices would go into effect ...

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

Novo Nordisk had a head start, winning approval to market its drug for obesity more than two years before Eli Lilly. ... Medicare will not pay for the drugs to treat obesity.